ENDOCRINOLOGY LABORATORY
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1964-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.evms.edu
Clinical Trials
52
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (43 trials with phase data)• Click on a phase to view related trials
Effectiveness of Smartphone Application for Adherence Support (Vuka+)
- Conditions
- Adherence, MedicationSmartphone Application
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Eastern Virginia Medical School
- Target Recruit Count
- 330
- Registration Number
- NCT06897059
- Locations
- 🇿🇦
Desmond Tutu Health Foundation, Cape Town, South Africa
Effect of Fiber Supplementation on the Need for Medication with Gestational Diabetes
- Conditions
- Gestational Diabetes Mellitus (GDM)
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Eastern Virginia Medical School
- Target Recruit Count
- 110
- Registration Number
- NCT06867861
- Locations
- 🇺🇸
Macon & Joan Brock Virginia Health Sciences at ODU, Norfolk, Virginia, United States
VR for Lac Repairs in Peds Emergency Department
- Conditions
- Laceration
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Eastern Virginia Medical School
- Target Recruit Count
- 91
- Registration Number
- NCT06516003
- Locations
- 🇺🇸
Children's Hospital of the King's Daughters, Norfolk, Virginia, United States
Ultrasound Findings in Diabetic Pregnancies
- Conditions
- Diabetes
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Eastern Virginia Medical School
- Target Recruit Count
- 156
- Registration Number
- NCT06407388
- Locations
- 🇺🇸
Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Eastern Virginia Medical School, Norfolk, Virginia, United States
Rectal Insert TAF/EVG Pre-Exposure Prophylaxis (RITE PrEP) Study
- Conditions
- Safety Issues
- Interventions
- Drug: TAF/EVG rectal insertDrug: Matching placebo rectal insert
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Eastern Virginia Medical School
- Target Recruit Count
- 24
- Registration Number
- NCT06274398
- Locations
- 🇺🇸
Emory Clinic, Atlanta, Georgia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
Tezepelumab Shows Remarkable 92% Reduction in Nasal Polyp Surgery Need in Phase 3 Trial
Phase 3 WAYPOINT trial demonstrates tezepelumab significantly reduced nasal polyp severity and improved nasal congestion scores in patients with severe chronic rhinosinusitis with nasal polyps.